Observational study of topical imiquimod immunotherapy in the treatment of difficult Lentigo Maligna

Clinical Medicine: Oncology

Volumn 2, Issue , 2008, Pages 551-554

  Craythorne, Emma E ^a   Lawrence, C M ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879530059     PISSN: None     EISSN: 11779314     Source Type: Journal    
DOI: 10.4137/cmo.s690     Document Type: Article

References (21)

1. Swetter, S.M., Boldrick, J.C., Jung, S.Y. et al. 2005. Oct. Increasing incidence of lentigo maligna melanoma subtypes: northern California and national trends 1990-2000. J. Invest Dermatol., 125(4):685-91.
2. Weinstock, M.A. and Sober, A.J. 1987. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br. J. Dermatol., 116:303-10.
3. Wayte, D.M. and Helwig, E.B. 1968. Melanotic Freckle of Hutchinson. Cancer, 21:893-901.
4. Roberts, D.L.L., Anstey, A.V., Barlow, R.J. et al. 2001. U.K. guidelines for the management of cutaneous melanoma. Br. J. Dermatol., 144:71-6.
5. Shyamala, C.H., Dinesh, S. et al. 2004. Surgical Margins for Lentigo Maligna and Lentigo Maligna Melanoma: The Technique of Mapped Serial Excision. Arch. Dermatol., 140:1087-92.
6. Huilgol, S.C., Selva, D., Chen, C. et al. 2004. Surgical margins for lentigo maligna and lentigo maligna melanoma. Arch. Dermatol., 140:1087-92.
7. Kelly, R.I., Cook, M.G. and Mortimer, P.S. 1994. Aggressive amelanotic lentigo maligna. Br. J. Dermatol., 131:562.
8. Rivers, J.K. and McCarthy, W.H. 1991. No effect of topical tretinoin on lentigo maligna. Arch. Dermatol., 127:129.
9. McKenna, D.B., Cooper, E.J. and Kavanagh, G.M. 2000. Amelanotic malignant melanoma following cryosurgery for atypical lentigo maligna. Clin. Exp. Dermatol., 25:60.
10. Wolf, H.I., Ceronni, L., Kodama, K. et al. 2005. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch. Dermatol., 141:510-4.
11. Ahmed, I. and Berth-Jones, J. 2000. Imiquimod: a novel treatment for lentigo maligna. Brit. J. Dermatol., 143:843-5.
12. Munoz, C.M., Sanchez, J.L. and Martin-Garcia, R.F. 2004. Successful treatment of persistent melanoma in situ with 5% imiquimod cream. Dermatol. Surg., 30:1543-5.
13. Stanley, M.A. 2002. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin. Exp. Dermatol., 27:571-7.
14. Meyer, T., Nindl, I., Schmook, T. et al. 2003. Induction of apoptosis by toll like receptor 7 agonist in tissue cultures. Br. J. Dermatol., 149(suppl 66):9-13.
15. Salasche, S.J., Levine, N. and Morrison, L. 2002. Cycle therapy of actinic keratosis of the face and scalp with 5% topical imiquimod cream: An open label trial. J. Am. Acad. Dermatol., 47:571-7.
16. Fleming, C.J., Bryden, A.M., Evans, A. et al. 2004. A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br. J. Dermatol., 151:485-8.
17. Fisher, G.H. and Lang, P.G. 2003. Treatment of melanoma in situ on sun damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease. Arch. Dermatol., 139:945-7.
18. Powell, A.M., Russell-Jones, R. and Barlow, R.J. 2004. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin. Exp. Dermatol., 29:15-21.
19. Naylor, M.F., Crowson, N., Kuwahara, R. et al. 2003. Treatment of lentigo maligna with topical imiquimod. Brit. J. Derm, 149:66-9.
20. Hanger, C., Dalrymple, J. and Hepburn, D. 2005. Systemic side effects from topical imiquimod. N Z Med. J., 118:U1682.
21. Bourguignon, R. et al. 2005. Sep. How I treat . lentigo maligna by topical imiquimod. Rev. Med. Liege., 60(9):691-4.